Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.

Tiziana Life Sciences (Nasdaq: TLSA) announced a collaboration with Parexel to conduct a global Phase 1b/2 trial using take-home capsules of Foralumab, the only fully human anti-CD3 monoclonal antibody, for moderate to severe Crohn's Disease.

This study will enroll 60 patients across the U.S. and Europe, aiming to evaluate safety and efficacy. The Crohn's Disease therapeutics market is projected to reach $4.7 billion by 2025, emphasizing the potential of Foralumab as a safer alternative to intravenous therapies, improving patient compliance and outcomes.

Tiziana Life Sciences (Nasdaq: TLSA) announced a clinical study for nasally administered Foralumab in COVID-19 patients in Brazil, starting November 3, 2020. This collaboration includes Harvard Medical School and aims to address Brazil's critical COVID-19 situation, with nearly 5.5 million cases reported. The trial seeks to demonstrate the drug's potential to enhance nasal immunity and suppress inflammation associated with the disease. Clinical data is anticipated by year-end, following a patent filed for its use in COVID-19 treatment.

Tiziana Life Sciences plc (Nasdaq: TLSA) has announced the timetable for the demerger of Accustem Sciences Limited, which involves spinning off its StemPrintER technology for predicting breast cancer recurrence. The StemPrintER demonstrated superior accuracy over Oncotype DX in predicting the 10-year risk for over 800 ER+/HER2-breast cancer patients. Key dates for the demerger include October 27, 2020, for court approval, and November 6, 2020, as the record date for ADR holders. A new ADR program for Accustem is in the works, with expected timelines aligned for effective registration and trading.

Tiziana Life Sciences (TLSA) announced that all resolutions were passed at the General Meeting on October 2, 2020. Key dates regarding the demerger of Accustem Sciences Limited, which will re-register as Accustem Sciences Plc, are outlined, including a court hearing on October 14 and completion of the demerger on October 30. The company received clearance from HMRC confirming that the demerger is for bona fide commercial reasons, ensuring shareholders will not face capital gains tax liabilities from receiving Accustem shares. Full voting results will be available on the company’s website.

Tiziana Life Sciences plc (NASDAQ: TLSA) announced an interview with CEO Dr. Kunwar Shailubhai, set to air on The RedChip Money Report on September 27, 2020. The discussion will cover the spinout of StemPrintER into a new entity, Accustem Sciences, and the upcoming clinical study of Foralumab for COVID-19 in Brazil. Tiziana is also advancing phase 2 studies for the orally and nasally administered Foralumab, targeting various autoimmune diseases, while working on an anti-IL6R mAb for COVID-19 treatment.

Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C. Wainwright & Co., available on their website. The company focuses on developing novel therapies for oncology, inflammation, and infectious diseases. Tiziana is advancing its pipeline, including phase 2 studies for foralumab, a human anti-CD3 monoclonal antibody targeting Crohn’s Disease and multiple sclerosis. They are also accelerating development of an anti-IL6R monoclonal antibody aimed at treating IL6-induced inflammation, particularly in COVID-19 patients.

Tiziana Life Sciences (NASDAQ: TLSA) announced a collaborative clinical study for the nasal administration of Foralumab in COVID-19 patients in Brazil, aimed at reducing severe symptoms associated with the disease. The study is anticipated to start soon, with preliminary data expected by the end of 2020. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in modulating the immune system, particularly in mitigating cytokine storms that lead to respiratory failure. The innovative approach may significantly impact COVID-19 treatment strategies.

Tiziana Life Sciences (TLSA) announced plans to demerge its StemPrintER asset into Accustem Sciences Limited, an independently listed public company. StemPrintER, a genomic-based assay, is noted for its 40% higher accuracy compared to the Oncotype DX assay for predicting breast cancer recurrence. A shareholder meeting is scheduled for October 2, 2020, with a record date for a 1:1 share dividend on October 30, 2020. Accustem aims for a late Q4 2020 listing on the London Stock Exchange and plans to seek CE Mark approval in November.